Pharmaceuticals
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high...
2021-07-22 13:00
2974
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-07-22 09:27
2589
Joysbio's COVID-19 RAPID tests detect NEW SARS-COV-2 variants
TIANJIN, China, July 22, 2021 /PRNewswire/ -- Joysbio, one of the world's leading manufacturers of lateral flow rapid test kits, has proven that their SARS-CoV-2 (COVID-19) antigen tests can detect new variants, including the Delta variant that's sweeping the world. With over 100 million tests so...
2021-07-22 08:37
2900
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients w...
2021-07-22 08:30
2658
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...
2021-07-21 22:00
11587
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...
2021-07-20 20:00
1432
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
SHANGHAI, July 20, 2021 /PRNewswire/ -- Everest Medicines
2021-07-20 18:42
4798
Juventas Cell Therapy Ltd. Closes Series C Financing to Advance the "Rapid Commercialization and Internationalization" Development Strategy
TIANJIN, China, July 20, 2021 /PRNewswire/ -- Juventas Cell Therapy Ltd., a Chinese biopharmaceutical company announced the close of a $60 million+ Series C financing led by CICC Capital and Oceanpine Capital. The co-investors include Delian Capital and existing investors such as Jiadao Private C...
2021-07-20 10:47
1736
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcomes
The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies SANTA CLARA, Calif., July 20, 2021 /PRNewswire/ -- Based on its recent analysis of the global clinical research organization (CRO) market,Frost & Sullivan recognizes l...
2021-07-20 01:47
1662
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstratedpotent inhibition of Beta and Gamma variant...
2021-07-19 19:21
17062
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax
SUZHOU, China, and ROCKVILLE, Md., July 19, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative ...
2021-07-19 18:41
3368
Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
* The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies * TALENT is the world's first phase III clinical trial of the new long-acting HIV...
2021-07-19 16:23
2769
YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from the UAE
BEIJING, July 19, 2021 /PRNewswire/ -- YishengBio Co., Ltd ("YishengBio") today announced that it has received IND clearance for PIKA recombinant COVID-19 vaccine to conduct Phase I clinical trial from United Arab Emirates Ministry of Health & Prevention. PIKA recombinant COVID-19 vaccine is a PI...
2021-07-19 09:00
2730
Bioelectronica Announces Hypercell™ Expansion for Antibody Discovery, Closing of Oversubscribed Series A Financing, Powering Local Hiring Growth and Expansion of Facilities in Reno
RENO, Nev., July 19, 2021 /PRNewswire/ -- Bioelectronica® Corporation ("Bioelectronica") announced today that it has secured an undisclosed amount in its Series A financing round due to increased interest in Hypercell™, a new hardware tool that can be used to discover new antibodies using compute...
2021-07-19 08:59
2436
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced thatParaguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emerg...
2021-07-16 14:41
36488
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-16 08:00
8014
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatMovement Disorders, the official jou...
2021-07-15 21:52
36659
Atonarp announces innovative new metrology platform Aston, aimed at increasing yield, throughput, and efficiency in semiconductor manufacturing processes
TOKYO, July 15, 2021 /PRNewswire/ -- Atonarp, a leading manufacturer of molecular sensing and diagnostics products for the semiconductor, healthcare, and pharma industries, today announcedAston, an innovative in-situ semiconductor metrology platform with an integrated plasma ionization source. ...
2021-07-15 21:15
3121
Cigna International finds community spirit and duty to society top driver of COVID-19 vaccine uptake
Key research findings: * Vaccine acceptance continues to improve – steady increase in vaccine acceptance, 69% up from 63% in three months * Urgency has increased – those waiting to get a vaccination until more people have had their first one dropped 8% in three months, from 50% to 42% * Vac...
2021-07-15 15:30
45530
Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005
SUZHOU, China, July 15, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed...
2021-07-15 11:23
2185
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714